Table 1 Baseline characteristic and outcome data
From: Low dose statins improve prognosis of ischemic stroke patients with intravenous thrombolysis
Variables | Low dose statin group(N = 180) | Control group (N = 35) | P* |
|---|---|---|---|
Age, years | 70.67(12.055) | 72.20(14.485) | 0.508 |
Female,% | 95(52.8) | 18(51.4) | 0.884 |
Admission NIHSS score | 8(4–14) | 15(9–18) | < 0.001 |
Antiplatelet Drug In Hospital,% | 160(88.9) | 8(22.9) | < 0.001 |
Cardioembolic,% | 63(35.0) | 20(57.1) | 0.014 |
Anticoagulation In Hospital,% | 23(12.8) | 7(20.0) | 0.286 |
Systolic Blood Pressure, mmHg | 148.51(24.653) | 153.17(32.198) | 0.333 |
Diastolic Blood Pressure, mmHg | 84.44(16.269) | 84.91(17.382) | 0.876 |
Smoking,% | 59(32.8) | 10(28.6) | 0.696 |
Hypertension,% | 85(47.2) | 18(51.4) | 0.713 |
Diabetes Mellitus,% | 34(18.9) | 8(22.9) | 0.642 |
Coronary heart disease,% | 22(12.2) | 4(11.4) | 0.894 |
Atrial fibrillation,% | 46(25.6) | 17(48.6) | 0.006 |
Antiplatelet drug,% | 22 (12.2) | 2(5.7) | 0.827 |
Antihypertensive,% | 63(35.0) | 15(42.9) | 0.514 |
Hypoglycaemic,% | 24(15.3) | 6(17.1) | 0.716 |
Anticoagulation,% | 12(6.7) | 4(11.4) | 0.394 |
Platelet, mmol/l | 180.63(52.683) | 173.91(58.295) | 0.499 |
INR | 0.98(0.106) | 0.99(0.110) | 0.508 |
ALT, mmol/l | 21.56(11.390) | 22.14(12.910) | 0.785 |
Creatinine, mmol/l | 77.84(26.317) | 82.51(28.485) | 0.344 |
Glucose, mmol/l | 7.82(2.619) | 7.99(3.447) | 0.728 |
Triglyceride, mmol/l | 1.72(1.388) | 1.57(0.993) | 0.544 |
Total cholesterol, mmol/l | 4.52(1.040) | 4.23(0.895) | 0.123 |
HDL-C, mmol/l | 1.30(0.396) | 1.30(0.444) | 0.956 |
LDL-C, mmol/l | 2.67(0.908) | 2.45(0.661) | 0.095 |
NIHSS improvement,% | 15(42.9) | 145(80.6) | < 0.001 |
FFO,% | 15(42.9) | 121(67.2) | < 0.001 |
ICH,% | 15(42.9) | 19(10.6) | < 0.001 |
Gastrointestinal Haemorrhage,% | 4(11.4) | 1(0.6) | 0.003 |
Death within 2 years,% | 24(68.6) | 15(8.3) | < 0.001 |